STOCK TITAN

Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Very Positive)
Tags

Geron (Nasdaq: GERN) has announced the granting of equity awards to three newly hired employees as inducement for their employment. The awards, granted on March 17, 2025, consist of:

  • 150,000 shares in stock options with an exercise price of $1.74 per share
  • 75,000 shares in restricted stock units (RSUs)

The stock options have a 10-year term with a vesting schedule of 12.5% after six months and the remaining shares vesting over 42 months. RSUs vest 25% annually over four years. These awards were granted under Geron's 2018 Inducement Award Plan and comply with Nasdaq Listing Rule 5635(c)(4).

Geron (Nasdaq: GERN) ha annunciato l'assegnazione di premi azionari a tre nuovi dipendenti come incentivo per il loro impiego. I premi, concessi il 17 marzo 2025, consistono in:

  • 150.000 azioni in opzioni su azioni con un prezzo di esercizio di $1,74 per azione
  • 75.000 azioni in unità azionarie vincolate (RSU)

Le opzioni su azioni hanno una durata di 10 anni con un piano di maturazione del 12,5% dopo sei mesi e le restanti azioni che maturano in 42 mesi. Le RSU maturano il 25% annualmente per quattro anni. Questi premi sono stati concessi nell'ambito del Piano di Premi di Incentivo del 2018 di Geron e sono conformi alla Regola di Registrazione Nasdaq 5635(c)(4).

Geron (Nasdaq: GERN) ha anunciado la concesión de premios en acciones a tres nuevos empleados como incentivo para su contratación. Los premios, otorgados el 17 de marzo de 2025, consisten en:

  • 150,000 acciones en opciones sobre acciones con un precio de ejercicio de $1.74 por acción
  • 75,000 acciones en unidades de acciones restringidas (RSUs)

Las opciones sobre acciones tienen un plazo de 10 años con un calendario de adquisición del 12.5% después de seis meses y el resto de las acciones adquiriéndose en 42 meses. Las RSUs se adquieren al 25% anualmente durante cuatro años. Estos premios se concedieron bajo el Plan de Premios por Inducción de 2018 de Geron y cumplen con la Regla de Listado 5635(c)(4) de Nasdaq.

Geron (Nasdaq: GERN)은 세 명의 새 직원에게 고용 유인을 위해 주식 보상을 부여했다고 발표했습니다. 이 보상은 2025년 3월 17일에 부여되었으며, 다음으로 구성됩니다:

  • 주당 $1.74의 행사 가격으로 150,000주에 대한 주식 옵션
  • 75,000주의 제한된 주식 단위(RSU)

주식 옵션은 10년의 기간을 가지며, 6개월 후 12.5%가 베스팅되고 나머지 주식은 42개월에 걸쳐 베스팅됩니다. RSU는 4년 동안 매년 25%씩 베스팅됩니다. 이 보상은 Geron의 2018년 유인 보상 계획에 따라 부여되었으며, Nasdaq 상장 규칙 5635(c)(4)를 준수합니다.

Geron (Nasdaq: GERN) a annoncé l'octroi de récompenses en actions à trois nouveaux employés comme incitation à leur embauche. Les récompenses, accordées le 17 mars 2025, consistent en :

  • 150 000 actions sous forme d'options d'achat d'actions avec un prix d'exercice de 1,74 $ par action
  • 75 000 actions sous forme d'unités d'actions restreintes (RSU)

Les options d'achat d'actions ont une durée de 10 ans avec un calendrier d'acquisition de 12,5 % après six mois et le reste des actions étant acquis sur 42 mois. Les RSU acquièrent 25 % annuellement sur quatre ans. Ces récompenses ont été accordées dans le cadre du Plan d'Octroi d'Incentives de 2018 de Geron et respectent la Règle de Cotation Nasdaq 5635(c)(4).

Geron (Nasdaq: GERN) hat die Gewährung von Aktienoptionen an drei neu eingestellte Mitarbeiter als Anreiz für ihre Beschäftigung angekündigt. Die Auszeichnungen, die am 17. März 2025 gewährt wurden, bestehen aus:

  • 150.000 Aktien in Form von Optionen mit einem Ausübungspreis von $1,74 pro Aktie
  • 75.000 Aktien in Form von eingeschränkten Aktieneinheiten (RSUs)

Die Aktienoptionen haben eine Laufzeit von 10 Jahren mit einem Vesting-Zeitplan von 12,5% nach sechs Monaten und die verbleibenden Aktien vesten über 42 Monate. Die RSUs vesten jährlich zu 25% über vier Jahre. Diese Auszeichnungen wurden im Rahmen des Geron 2018 Inducement Award Plans gewährt und entsprechen der Nasdaq-Listing-Regel 5635(c)(4).

Positive
  • None.
Negative
  • None.

FOSTER CITY, Calif.--(BUSINESS WIRE)-- Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that it has granted equity awards covering an aggregate of 225,000 shares of its common stock, consisting of stock options to purchase an aggregate of 150,000 shares of common stock and restricted stock units (“RSUs”) representing an aggregate of 75,000 shares of common stock, to three newly hired employees as an inducement material to their acceptance of employment with the Company.

The stock options and RSUs were granted on March 17, 2025. The stock options have an exercise price of $1.74 per share, which is equal to the closing price of Geron common stock on the grant date, have a 10-year term and vest over four years, with 12.5% of the shares underlying the options vesting on the six-month anniversary of commencement of employment of each employee and the remaining shares vesting over the following 42 months in equal installments of whole shares, subject to continued employment with Geron through the applicable vesting dates. The RSUs vest as to 25% of the award on each anniversary of the grant date, subject to continued employment with Geron through the applicable vesting dates. All of the equity awards were granted by the Compensation Committee of Geron’s Board of Directors in accordance with Nasdaq Listing Rule 5635(c)(4) and are subject to the terms and conditions of Geron’s 2018 Inducement Award Plan and the forms of stock option and RSU agreements under the plan.

About Geron

Geron is a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer. Our first-in-class telomerase inhibitor RYTELO® (imetelstat) is approved in the United States and the European Union for the treatment of certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion dependent anemia. We are also conducting a pivotal Phase 3 clinical trial of imetelstat in JAK-inhibitor relapsed/refractory myelofibrosis (R/R MF), as well as studies in other myeloid hematologic malignancies. Inhibiting telomerase activity, which is increased in malignant stem and progenitor cells in the bone marrow, aims to reduce proliferation and induce death of malignant cells. To learn more, visit www.geron.com or follow us on LinkedIn.

Aron Feingold

Vice President, Investor Relations and Corporate Communications

Kristen Kelleher

Associate Director, Investor Relations and Corporate Communications

investor@geron.com

media@geron.com

Source: Geron Corporation

FAQ

What equity awards did Geron (GERN) grant to new employees in March 2025?

Geron granted 225,000 shares total: 150,000 shares in stock options at $1.74 per share and 75,000 shares in RSUs to three new employees.

What is the vesting schedule for GERN's March 2025 stock option grants?

The stock options vest 12.5% after six months, with remaining shares vesting over 42 months in equal installments.

How long is the vesting period for Geron's (GERN) March 2025 RSU grants?

The RSUs vest over 4 years, with 25% vesting on each anniversary of the grant date.

What was the exercise price for GERN's March 2025 stock option grants?

The stock options were granted with an exercise price of $1.74 per share, matching Geron's closing price on March 17, 2025.
Geron Corp

NASDAQ:GERN

GERN Rankings

GERN Latest News

GERN Stock Data

961.73M
632.75M
0.1%
78.42%
9.17%
Biotechnology
Pharmaceutical Preparations
Link
United States
FOSTER CITY